News
WUXAY
4.770
-2.85%
-0.140
Weekly Report: what happened at WUXAY last week (0422-0426)?
Weekly Report · 6d ago
Artisan Sustainable Emerging Markets Fund Q1 2024 Commentary
Seeking Alpha · 04/24 15:50
Weekly Report: what happened at WUXAY last week (0415-0419)?
Weekly Report · 04/22 09:48
Weekly Report: what happened at WUXAY last week (0408-0412)?
Weekly Report · 04/15 09:44
Weekly Report: what happened at WUXAY last week (0401-0405)?
Weekly Report · 04/08 09:46
Weekly Report: what happened at WUXAY last week (0325-0329)?
Weekly Report · 04/01 09:46
Week In Review: AriBio Sells China Rights To Alzheimer's Candidate In $770M Deal
Seeking Alpha · 03/31 08:50
More On WuXi, And It Isn't Good
Reuters is reporting that US legislators have had a classified briefing about WuXi AppTec Co., Ltd. WuXi is one of the most prominent Chinese outsourcing companies. There are bills in the works that would restrict the ability of US companies to work with these contractors. The BIO trade group announced that it was severing contact with WuXi.
Seeking Alpha · 03/30 04:10
Weekly Report: what happened at WUXAY last week (0318-0322)?
Weekly Report · 03/25 09:47
Week In Review: 3 Multinationals Plan Investments In Southeast Asia Facilities
Shanghai WuXi Biologics has broken ground on a $1.4 billion facility in Singapore. Novo Nordisk announced plans to invest $556 million to expand its Tianjin production facility. BeiGene was approved to market a new drug in the US.
Seeking Alpha · 03/24 11:15
WuXi AppTec reports FY results
WuXi AppTec reports FY revenue up 2.5% year-over-year to RMB40,341 million. Excluding COVID-19 Commercial Projects, revenue was up 25.6%. The company also reported a 15.7% increase in diluted earnings per share to $3.68.
Seeking Alpha · 03/18 18:17
Weekly Report: what happened at WUXAY last week (0311-0315)?
Weekly Report · 03/18 09:46
Week In Review: Under Pressure From U.S. Congress, WuXi AppTec Resigns From BIO
Germany's Boehringer Ingelheim acquired an option to license drug candidates that treat all symptoms of schizophrenia. WuXi AppTec forced to resign from BIO due to pressure from the US Congress. ChinaBio filed for a Hong Kong IPO to support commercialization of its diabetes and obesity drug.
Seeking Alpha · 03/17 07:20
Biotech group backs anti-China bill; part ways with WuXi AppTec
Healthcare Biotech group backs anti-China bill; part ways with WuXi AppTec. The biotech industry's top lobbying group backs a proposed bill against a group of Chinese biopharma firms. The proposed legislation aims to restrict Chinese biotech companies from accessing federal funds.
Seeking Alpha · 03/14 11:20
Weekly Report: what happened at WUXAY last week (0304-0308)?
Weekly Report · 03/11 09:45
Weekly Report: what happened at WUXAY last week (0226-0301)?
Weekly Report · 03/04 09:46
Weekly Report: what happened at WUXAY last week (0219-0223)?
Weekly Report · 02/26 09:50
Weekly Report: what happened at WUXAY last week (0212-0216)?
Weekly Report · 02/19 09:51
Weekly Report: what happened at WUXAY last week (0205-0209)?
Weekly Report · 02/12 09:47
I-Mab to divest Chinese assets amid rising geopolitical tensions
Healthcare I-Mab to divest Chinese assets amid rising geopolitical tensions. U.S. Biopharma firm to divest the company's assets and business operations in China. The move follows bipartisan legislation introduced in Congress to restrict federal funds to Chinese firms. Biotechs with roots in China have sharply underperformed over the past six months.
Seeking Alpha · 02/07 16:28
More
Webull provides a variety of real-time WUXAY stock news. You can receive the latest news about Wuxi Apptec through multiple platforms. This information may help you make smarter investment decisions.
About WUXAY
WuXi AppTec Co., Ltd. is a China-based investment holding company principally engaged in the provision of new drug research and development (R&D), production and supporting services, as well as related technology platform services. The Company is mainly engaged in the discovery, development and production of small molecule drugs, cell therapies and gene therapies, as well as providing testing services for medical devices. The Company mainly conducts its businesses through four segments, including China-based Laboratory Services segment, Contract Manufacturing organization/contract development and manufacturing organization services (CMO/CDMO services) segment, US-based Laboratory Services segment and Clinical Research segment.